As researchers explore new treatment options for Cannabinoid Hyperemesis Syndrome (CHS), some people have wondered whether GLP-1 medications-the same drugs used for diabetes and weight management-might help with cannabis cessation or CHS symptoms. These medications, which include semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda), have gained attention for their effects on appetite and substance use patterns.

The short answer is: There is currently no research evidence to support using GLP-1 medications specifically for treating cannabis hyperemesis syndrome or helping CHS patients stop using cannabis. While these medications have shown promise in other contexts, no studies have examined their effectiveness for CHS patients.

What Are GLP-1 Medications?

GLP-1 (glucagon-like peptide-1) receptor agonists are medications originally developed for type 2 diabetes. They work by mimicking a hormone that helps regulate blood sugar and appetite. More recently, some formulations have been approved for weight management because they can reduce appetite and slow stomach emptying.

These medications have also been studied for their potential effects on substance use behaviors, including alcohol use disorder and other addictions. This has led some to wonder whether they might help people with CHS stop using cannabis, which is the only true cure for the condition.

The Research Gap

A comprehensive review of the medical literature searched over 138 million academic papers to find studies examining whether GLP-1 medications are more effective than standard treatments for helping CHS patients stop using cannabis. The search found zero studies that directly addressed this question.

This is a significant research gap. CHS is a serious condition that can cause life-threatening dehydration and electrolyte imbalances. Many people with CHS struggle to stop using cannabis, and standard antiemetic medications often don’t provide adequate relief during acute episodes. If GLP-1 medications could help with cannabis cessation in CHS patients, it would be valuable information-but we simply don’t have that data yet.

What the Available Research Actually Shows

While there are no studies on GLP-1 medications for CHS, there is one study that examined semaglutide in relation to cannabis use-but it looked at a completely different population and condition.

The study examined patients with obesity and type 2 diabetes who were prescribed semaglutide or other medications. It found that people taking semaglutide had lower rates of being diagnosed with cannabis use disorder compared to people taking other medications for their conditions.

Specifically, the study found:

• About 44% lower risk of developing new cannabis use disorder in patients with obesity
• About 38% lower risk of recurring cannabis use disorder in patients with obesity
• Similar patterns in patients with type 2 diabetes

Why This Doesn’t Apply to CHS

While these findings might seem promising, they don’t tell us anything about whether GLP-1 medications could help CHS patients. Here’s why:

Different Population

The study didn’t include any patients with cannabis hyperemesis syndrome. Instead, it looked at people with obesity and diabetes who happened to have cannabis use disorder. CHS is a distinct condition that affects people differently than general cannabis use disorder.

CHS patients often have a specific pattern of symptoms-severe cyclical vomiting, nausea, and abdominal pain that’s temporarily relieved by hot showers. They may have been using cannabis for years before developing CHS, and the condition creates a unique challenge for cessation because symptoms can worsen during withdrawal periods.

Different Outcomes

The study measured medical diagnoses of cannabis use disorder through electronic health records, not actual cannabis cessation or CHS symptom relief. It didn’t track:

• Whether people actually stopped using cannabis
• How much their cannabis use decreased
• Whether CHS symptoms improved
• Emergency department visits for CHS
• Quality of life measures

These are the outcomes that matter for CHS patients, but the study didn’t measure them.

Different Context

The study was observational and retrospective, meaning it looked back at existing medical records rather than actively testing whether semaglutide helps people stop using cannabis. This type of study can show associations but cannot prove that semaglutide caused the lower rates of cannabis use disorder diagnoses.

There could be many reasons why people taking semaglutide had fewer cannabis use disorder diagnoses that have nothing to do with the medication itself. For example, people who are actively managing their diabetes or obesity with medication might be more engaged in their healthcare overall, or they might have different motivations or support systems.

The Need for Dedicated Research

The research review concluded that “the comparative effectiveness of GLP intervention versus standard treatment for cannabis cessation in CHS patients remains unknown and requires dedicated research in this specific clinical population.”

This means we need studies that:

• Specifically recruit patients with diagnosed CHS
• Compare GLP-1 medications to standard CHS treatment protocols
• Measure actual cannabis cessation outcomes (not just diagnoses)
• Track CHS symptom resolution
• Monitor safety and side effects in CHS patients
• Follow patients long enough to see if cessation is sustained

Until such research is conducted, we cannot know whether GLP-1 medications might be helpful for CHS patients trying to stop using cannabis.

Why This Matters

CHS is a challenging condition to treat. Standard antiemetic medications like ondansetron and prochlorperazine are often ineffective, which is why researchers have been exploring new treatment options like aprepitant. The fact that there’s no research on GLP-1 medications for CHS represents a missed opportunity to potentially help people who are struggling.

If GLP-1 medications could help CHS patients stop using cannabis-which is the only true cure for the condition-that would be valuable information. But we need proper research to answer that question, not assumptions based on studies in completely different populations.

What This Means for People with CHS

If you’re dealing with CHS and wondering whether a GLP-1 medication might help you stop using cannabis, here’s what you should know:

There’s No Evidence Yet

Currently, there’s no research to support using GLP-1 medications specifically for CHS or cannabis cessation in CHS patients. This doesn’t mean they definitely won’t work-it just means we don’t have the data to know either way.

Standard Approaches Remain the Foundation

The only proven cure for CHS is complete and permanent cessation of cannabis use. While this can be challenging, especially during withdrawal periods when symptoms may temporarily worsen, it’s the only approach with clear evidence of effectiveness.

Treatment During Episodes

For managing acute CHS episodes, emerging treatments like aprepitant may be more effective than traditional antiemetics. Supportive care including IV fluids for hydration is crucial, as severe dehydration can be life-threatening.

Talk to Your Doctor

If you’re interested in exploring GLP-1 medications, discuss this with your healthcare provider. They can help you understand:

• Whether a GLP-1 medication might be appropriate for other health conditions you have
• The potential risks and benefits
• That there’s no evidence specifically for CHS
• Other options for supporting cannabis cessation

Your doctor can also help you access resources for stopping cannabis use, such as addiction medicine specialists or outpatient programs.

The Research Landscape Moving Forward

The fact that semaglutide showed associations with lower cannabis use disorder rates in other populations has generated interest in whether these medications might help with substance use more broadly. However, translating findings from one population to another requires careful research.

For CHS specifically, we need studies designed to answer the right questions:

• Can GLP-1 medications help CHS patients achieve and maintain cannabis cessation?
• Do they provide any benefit beyond standard cessation support?
• Are they safe for CHS patients, who may have specific health considerations?
• How do they compare to other emerging treatments like aprepitant for managing acute episodes?

These are important questions that deserve dedicated research. Until that research is conducted, we’re operating without evidence-which means we can’t confidently recommend GLP-1 medications for CHS, even if they might theoretically have benefits.

Conclusion

GLP-1 medications have shown promise in various contexts, from diabetes management to weight loss to potentially reducing substance use in some populations. However, when it comes to cannabis hyperemesis syndrome specifically, we’re facing a significant research gap.

There is currently no evidence to support using GLP-1 medications for treating CHS or helping CHS patients stop using cannabis. The single study that examined these medications in relation to cannabis use looked at completely different populations and outcomes, so its findings don’t apply to CHS.

This doesn’t mean GLP-1 medications definitely won’t help-it just means we need proper research to find out. Until that research is conducted, the only proven cure for CHS remains complete and permanent cessation of cannabis use, supported by appropriate medical care during acute episodes.

If you’re struggling with CHS, focus on proven approaches: complete cessation, medical support during episodes, and emerging treatments like aprepitant that have shown promise specifically for CHS. As research continues to evolve, we may learn more about whether GLP-1 medications have a role to play-but for now, we’re working with the evidence we have, not the evidence we wish we had.